menu
Intellia Therapeutics Head office building

Investors
& Media

Press Releases

Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)

Read More

Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations

Read More
View All Press Releases

Upcoming
Events

Recent
Presentations

Stock Information

(Common Stock) Oct 29, 2026 — 8:02 AM EDT
Change
Volume
Today's Open
Previous Close
Today's High
Today's Low

Minimum 15 minutes delayed. Source: LSEG

RSS FEEDS
PRINT PAGE